73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1 CHICAGO, June 3, 2024 /PRNewswire/ — Johnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data […]
